By Fetty Rara
The maker of AstraZeneca (AZ) Covid-19 vaccine on Wednesday announced in a statement (here) that its treatment for individuals at risk of death from the virus showed good results in a late-stage trial.
The British-based pharmaceutical giant said jabs using its Evusheld vaccine “provided clinically and statistically significant protection against progression to severe Covid-19 or death”.
AZ said the phase-three trial using Evusheld involved a total 903 patients worldwide.
Professor of intensive care medicine at University College London, Hugh Montgomery said older adults, individuals with co-morbidities and those who are immune-compromised, remained at risk for poor outcomes from severe Covid-19.
He said additional options were needed to prevent disease progression and reduce the burden on healthcare systems, especially with the continued emergence of new variants.
Administration of Evusheld for individuals aged 12 and above or those who have had mild Covid-19 infection comprises two antibodies.
The European Union has approved the jab’s use, while the United States and Britain approved it with restrictions.
-BTS Media
